Special Issue "The Interplay of Gut Dysbiosis with Metabolic Syndrome"
Deadline for manuscript submissions: 31 January 2024 | Viewed by 1581
Interests: metabolic syndrome; high blood pressure and abnormal cholesterol levels; diabetes and insulin resistance; cardiovascular diseases; kidney damage and fibrosis; nano-medicine and toxicology
Special Issues, Collections and Topics in MDPI journals
Dysbiosis of the gut microbiota plays a crucial role in the pathogenesis of metabolic syndrome, both in human and animal models. Diet has a significant impact on both the microbial composition of the gut and its activities. This multi-component intestinal “superorganism” is thought to influence the metabolic equilibrium of the host. It controls how much energy is taken in, how fast the gut moves, how hungry the host is, how much glucose the host has in its blood, how the host liver uses fat, and how much fat the liver stores. Overgrowth of one species of microbes causes dysbiosis, and disturbed gut homeostasis is called dysbiosis. Disruption in the delicate equilibrium that exists between the microbes in the gut and the immune system of the host could ultimately result in the intestinal translocation of bacterial fragments and the development of "metabolic endotoxemia," which would then cause inflammation throughout the body as well as insulin resistance. This Special Issue will shed light on dysbiosis and its connections to ‘metabolic syndrome.” Dysbiosis causes a cluster of interrelated physiological, biochemical, clinical, and metabolic risk factors that are associated with an increased likelihood of developing cardiovascular disease and type 2 diabetes. The main characteristics of metabolic syndrome are elevated blood pressure, dyslipidemia (defined as increased triglycerides and reduced high-density lipoprotein cholesterol), elevated fasting glucose, and central obesity. Manipulation of gut microbiota through the administration of prebiotics or probiotics could reduce intestinal low-grade inflammation and improve gut barrier integrity, thereby improving metabolic balance and promoting weight loss. However, additional evidence is required to fully comprehend their clinical impact and the therapeutic application of dysbiosis and its link with metabolic syndrome.
We invite researchers working on the effects of gut dysbiosis on metabolic syndrome to submit original research articles or review papers for this Special Issue in order to advance our understanding of this complicated and intriguing topic. The following are examples of possible topics; however, this list is not exhaustive.
A cluster of interconnected physiological, biochemical, clinical, and metabolic risk factors are caused by gut dysbiosis. These risk factors are associated with an increased chance of developing cardiovascular disease and type 2 diabetes.
It is possible that strengthening the integrity of the gut barrier and reducing low-grade inflammation in the intestines might be accomplished through manipulation of the gut microbiota using prebiotics and probiotics. This would result in improved metabolic balance and the facilitation of weight reduction.
However, therapeutic approaches are necessary for the clinical symptoms of dysbiosis, and for the therapy and treatment of metabolic syndrome.
Dr. Shailendra Pratap Singh
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- gut microbiota dysbiosis
- metabolic syndrome
- immune system
- cardiovascular diseases